AR107261A1 - Vacuna marcadora de pestivirus - Google Patents
Vacuna marcadora de pestivirusInfo
- Publication number
- AR107261A1 AR107261A1 ARP160104074A ARP160104074A AR107261A1 AR 107261 A1 AR107261 A1 AR 107261A1 AR P160104074 A ARP160104074 A AR P160104074A AR P160104074 A ARP160104074 A AR P160104074A AR 107261 A1 AR107261 A1 AR 107261A1
- Authority
- AR
- Argentina
- Prior art keywords
- pestivirus
- erns gene
- mutant
- chimeric
- gene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24361—Methods of inactivation or attenuation
- C12N2770/24362—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Pestivirus mutante que tiene un genoma en donde el gen Erns está mutado, caracterizado porque el gen Erns mutado es un gen Erns quimérico, y el gen Erns quimérico se compone de una parte 5’ y una parte 3’, en donde la parte 5’ representa 60 - 95% del gen Erns quimérico, y la parte 3’ representa el resto del gen Erns quimérico, y en donde dicha parte 5’ se compone de la parte correspondiente de un gen Erns de un Pestivirus que es genéticamente distante del Pestivirus mutante, y en donde dicha parte 3’ se compone de la parte correspondiente de un gen Erns de un Pestivirus que es genéticamente cercano al Pestivirus mutante. Reivindicación 8: Método para la construcción de un Pestivirus mutante de acuerdo con cualquiera de las reivindicaciones 1 - 7, dicho método comprende la mutación del gen Erns de un genoma de Pestivirus, en un gen Erns quimérico como se define en la reivindicación 1. Reivindicación 10: Vacuna para animales que comprende un Pestivirus mutante de acuerdo con cualquiera de las reivindicaciones 1 - 7, o una célula huésped de acuerdo con la reivindicación 9, o cualquier combinación de las mismas, y un portador farmacéuticamente aceptable. Reivindicación 20: Kit de pruebas de diagnóstico que comprende un Pestivirus mutante de acuerdo con cualquiera de las reivindicaciones 1 - 7, o una proteína Erns quimérica expresada por el Pestivirus mutante. Reivindicación 21: Un método para controlar una infección con un Pestivirus en una población de animales del orden Artiodactyla, por el uso combinado de una vacuna de acuerdo con la reivindicación 10 y un kit de pruebas de diagnóstico de acuerdo con la reivindicación 20.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15203202 | 2015-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR107261A1 true AR107261A1 (es) | 2018-04-11 |
Family
ID=55085493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160104074A AR107261A1 (es) | 2015-12-30 | 2016-12-29 | Vacuna marcadora de pestivirus |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190240311A1 (es) |
EP (1) | EP3397280A1 (es) |
JP (1) | JP2019506850A (es) |
CN (1) | CN108430504A (es) |
AR (1) | AR107261A1 (es) |
AU (1) | AU2016382839A1 (es) |
BR (1) | BR112018013400A2 (es) |
CA (1) | CA3006921A1 (es) |
MX (1) | MX2018008085A (es) |
RU (1) | RU2018127402A (es) |
WO (1) | WO2017114778A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102018110208A1 (de) * | 2018-04-27 | 2019-10-31 | Stiftung Tierärztliche Hochschule Hannover | Gentechnisch veränderte Pestiviren und deren Verwendung als Markerimpfstoff |
JP6976621B1 (ja) * | 2021-02-04 | 2021-12-08 | 株式会社Icst | 検査器具、検査キットおよび検査方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1174506A1 (en) * | 2000-06-28 | 2002-01-23 | Stichting Dienst Landbouwkundig Onderzoek | C-terminal Erns peptide and analogues thereof |
AU2009323784B2 (en) * | 2008-12-03 | 2013-08-15 | Zoetis Services Llc | Bovine viral diarrhea virus with a modified Erns protein |
BR112014004261B8 (pt) * | 2011-08-24 | 2022-11-08 | Zoetis Llc | Diagnósticos de vacina melhorada |
EP2890707A1 (en) * | 2012-08-29 | 2015-07-08 | Intervet International B.V. | Marker vaccine |
-
2016
- 2016-12-23 BR BR112018013400A patent/BR112018013400A2/pt not_active Application Discontinuation
- 2016-12-23 US US16/066,218 patent/US20190240311A1/en not_active Abandoned
- 2016-12-23 AU AU2016382839A patent/AU2016382839A1/en not_active Abandoned
- 2016-12-23 CA CA3006921A patent/CA3006921A1/en not_active Abandoned
- 2016-12-23 EP EP16826054.5A patent/EP3397280A1/en not_active Withdrawn
- 2016-12-23 CN CN201680077202.3A patent/CN108430504A/zh active Pending
- 2016-12-23 WO PCT/EP2016/082537 patent/WO2017114778A1/en active Application Filing
- 2016-12-23 RU RU2018127402A patent/RU2018127402A/ru not_active Application Discontinuation
- 2016-12-23 MX MX2018008085A patent/MX2018008085A/es unknown
- 2016-12-23 JP JP2018534137A patent/JP2019506850A/ja active Pending
- 2016-12-29 AR ARP160104074A patent/AR107261A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
RU2018127402A (ru) | 2020-01-30 |
EP3397280A1 (en) | 2018-11-07 |
JP2019506850A (ja) | 2019-03-14 |
MX2018008085A (es) | 2018-08-23 |
RU2018127402A3 (es) | 2020-01-30 |
AU2016382839A1 (en) | 2018-06-21 |
BR112018013400A2 (pt) | 2018-12-18 |
CN108430504A (zh) | 2018-08-21 |
WO2017114778A1 (en) | 2017-07-06 |
US20190240311A1 (en) | 2019-08-08 |
CA3006921A1 (en) | 2017-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019010565A2 (pt) | aplicação viral de neoantígenos | |
CL2018000432A1 (es) | Vacunas terapéuticas contra el hpv18 | |
MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
EA201792663A1 (ru) | Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr | |
ECSP18083561A (es) | Proteínas de fusión gdf15 y usos de estas | |
BR112015002280A2 (pt) | produção de gado resistente a vfa por substituição de alelo | |
BR112018011881A2 (pt) | proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus | |
BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
BR112015024605A2 (pt) | sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo | |
SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
EA201890137A1 (ru) | Среда для культивирования клеток с добавлением таурина и способы применения | |
CL2016003096A1 (es) | Métodos para cosechar cultivos de células de mamífero | |
BR112017014031A2 (pt) | n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado. | |
BR112017005378A2 (pt) | composições que compreendem células recombinantes de bacillus e um outro agente de controle biológico. | |
BR112016022814A8 (pt) | composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico | |
BR112016007727A2 (pt) | célula hospedeira, métodos para produzir um glicoconjugado, uma célula hospedeira e uma proteína n-glicosilada, para tratar ou prevenir uma infecção em um indivíduo e para induzir uma resposta imune em um indivíduo, glicoconjugado, kit, e, plasmídeo isolado | |
MX2017007196A (es) | Fibroblastos de embrion de pollo inmortalizados. | |
BR112017005509A2 (pt) | composições que compreendem células recombinantes de bacillus e um outro agente de controle biológico. | |
BR112016023688A2 (pt) | célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada | |
CY1123144T1 (el) | Επαγωγη καρδιακης αναγεννησης μe microrna | |
EA202091349A1 (ru) | Способы культивирования клеток | |
AR113812A1 (es) | Estrategias para precisión en la edición del genoma | |
BR112018009097A8 (pt) | spodoptera frugiperda resistente a vip3a | |
SG11202009389QA (en) | Use of nw_003613638.1 in cho cell genome for stable expression of protein | |
CO2020013050A2 (es) | Enzimas quinureninasa humanas y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |